<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/3F7T-M688 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method GTA-6: HepG2 Hepatocarcinoma Apoptosis Assay</p><p><b>Protocol Abbreviation:</b> GTA-6</p><p><b>Protocol Version:</b> 1.1<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/3F7T-M688 >http://dx.doi.org/10.17917/3F7T-M688 </a></p><p><b>Protocol File:</b> protocols/20240410_18-32-28-420_NCL_Method_GTA-6.pdf<p><b>File Title:</b> GTA-6</p><p><b>Description:</b></b> This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade.  The protocol utilizes a fluorescent method to determine the degree of caspase-3 activation.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>